It’s not all about the CNS. High dose methotrexate in DLBCL

References

• Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 – the Southwest Oncology Group. JCO. 2009;27:114–119.
   PubMed Web of Science ®Google Scholar
• Jahnke K, Thiel E, Martus P, et al. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol. 2006;85:45–50.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Magagnoli M, Frezza G, et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma. 1999;32:571–576.
   PubMed Web of Science ®Google Scholar
• Ghose A, Elias HK, Guha G, et al. Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophylaxis-a systematic review of prospective studies. Clin Lymphoma Myeloma Leuk. 2015;15:451–457.
   PubMed Web of Science ®Google Scholar
• Kumar A, Vanderplas A, Lacasce AS, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012;118:2944–2951.
   PubMed Web of Science ®Google Scholar
• Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284–4289.
   PubMed Web of Science ®Google Scholar
• Ghose A, Kundu R, Latif T. Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma. Crit Rev Oncol Hematol. 2014;91:292–303.
   PubMed Web of Science ®Google Scholar
• Van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91:1178–1184.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34:3150–3156.
   PubMed Web of Science ®Google Scholar
• Goldschmidt N, Horowitz NA, Heffes V, et al. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse. Leuk Lymphoma. [cited 2019 Jan 28]; [9 p.]. DOI:10.1080/10428194.2018.1564823
   Web of Science ®Google Scholar
• Melen CM, Enblad G, Sonnevi K, et al. Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. Br J Haematol. 2016;175:614–622.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Bruno-Ventre M, Donadoni G, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol. 2015;168:654–662.
   PubMed Web of Science ®Google Scholar
• Strüßmann T, Fritsch K, Baumgarten A, et al. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation. Br J Haematol. 2017;178:927–935.
   PubMed Web of Science ®Google Scholar
• Wolfrom C, Hartmann R, Fengler R, et al. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol. 1993;11:827–833.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002–1006.
   PubMed Web of Science ®Google Scholar
• Gottlieb AJ, Anderson JR, Ginsberg SJ, et al. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851. Cancer. 1990;66:1888–1896.
   PubMed Web of Science ®Google Scholar
• Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18:1076–1088.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Sin-Ho J, Pitcher BN, et al. Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-Cell lymphoma: CALGB/Alliance 50303. Blood. 2016;128:469–469.
   Web of Science ®Google Scholar
• Younes A, Sehn LH, Johnson P, et al. A global, randomized, placebo-controlled, phase 3 study of ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with previously untreated non-germinal center B-cell-like (GCB) diffuse large B-cell Lymphoma (DLBCL). Blood. 2018;132:784–784.
   Web of Science ®Google Scholar